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http://dx.doi.org/10Major progress has been recently made in understanding the molecular pathogenesis of
myeloproliferative neoplasms (MPN). Mutations in one of four genesdJAK2, MPL, CALR,
and CSF3Rdcan be found in the vast majority of patients with MPN and represent driver
mutations that can induce the MPN phenotype. Hyperactive JAK/STAT signaling appears
to be the common denominator of MPN, even in patients with CALR mutations and the
so-called ‘‘triple-negative’’ MPN, where the driver gene mutation is still unknown. Mutations
in epigenetic regulators, transcription factors, and signaling components modify the course of
the disease and can contribute to disease initiation and/or progression. The central role of
JAK2 in MPN allowed development of small molecular inhibitors that are in clinical use
and are active in almost all patients with MPN. Advances in understanding the mechanism
of JAK2 activation open new perspectives of developing the next generation of inhibitors
that will be selective for the mutated forms of JAK2. Copyright  2015 ISEH - International
Society for Experimental Hematology. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Myeloproliferative neoplasms (MPN) are a group of dis-
eases characterized by increased proliferation of erythroid,
megakaryocytic, or granulocytic cells. The concept to
group several clinical entities under this umbrella goes
back to William Dameshek, who in 1951 recognized that
these disorders are caused by hyperproliferation of multiple
hematopoietic lineages in the bone marrow that proliferate
‘‘as a unit’’ [1]. Dameshek proposed the term myeloprolif-
erative disorders to indicate that these entities may repre-
sent a continuum of related syndromes. He also proposed
that the proliferative activity could be perhaps due ‘‘to a
hitherto undiscovered stimulus’’ [1]. However, the finding
that bone marrow and peripheral blood cells from MPN
patients can produce erythroid colonies in vitro in the
absence of added growth factors indicated the cell autono-
mous nature of these diseases [2], and the clonal origin of
peripheral blood cells of MPN patients was later proven
by analyzing X-chromosome inactivation patterns [3].
The classification proposed by the World Health Organiza-
tion (WHO) is currently most widely used and defines eight
entities (Table 1) [4]. This classification will soon be
revised and modified to incorporate recent advances ino: Radek C. Skoda, Department of Biomedicine,
logy, University Hospital Basel, Hebelstrasse 20,
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.1016/j.exphem.2015.06.007the molecular characterization of these diseases [5]. In
this review, we will focus primarily on the so-called Phila-
delphia chromosome–negative or BCR-ABL1-negative
MPN, that is, polycythemia vera (PV), essential thrombocy-
themia (ET), primary myelofibrosis (PMF), and chronic
neutrophilic leukemia (CNL).Driver mutations that cause myeloproliferation in
Ph-negative MPN
Only 10 years ago, essentially nothing was known about the
molecular pathogenesis of MPN. The first gene mutation
described in 2005, JAK2-V617F, turned out to be the
most important and most frequently recurring somatic
mutation in MPN [6–9]. The frequency of JAK2-V617F is
around 95% in PV and between 50% and 60% in ET and
PMF (Fig. 1). Expression of JAK2-V617F in cell lines ab-
rogates their growth factor dependence, and retroviral
expression of JAK2-V617F in hematopoietic cells in mouse
models leads to an MPN phenotype resembling the human
PV [6,10–13]. These data indicated that the JAK2-V617F
mutation results in a gain of function. Somatic mutations
in other positions in JAK2 have been subsequently found
in PV (JAK2 exon 12 mutations) [14] and B-cell acute lym-
phocytic leukemias (JAK2 exon 16 mutations) [15–19].
More recently, a number of JAK2 germline mutationsatology. Published by Elsevier Inc. This is an open access article under the
Table 1. 2008 classification of myeloproliferative neoplasms by the
World Health Organisation [4]
1 Chronic myelogenous leukemia, BCR-ABL1 positive (CML)
2 Chronic neutrophilic leukemia (CNL)
3 Polycythemia vera (PV)
4 Primary myelofibrosis (PMF)
5 Essential thrombocythemia (ET)
6 Chronic eosinophilic leukemia, not otherwise specified (CEL-NOS)
7 Mastocytosis
8 Myeloproliferative neoplasm, unclassifiable (MPN-U)
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associated with a thrombocytosis phenotype [20–22].
Activating mutations in the thrombopoietin (Tpo) recep-
tor, MPL, can be found either as germline mutations in rare
cases of familial thrombocytosis (MPL-S505N) [23] or as
somatic mutations that occur in 3%–8% of patients with
PMF or ET (MPL-W515) [24,25]. The mechanism of
how these missense mutations result in Tpo-independent
signaling by the mutant Mpl protein involves alterations
in the geometry of Mpl dimers and the attached Jak2 pro-
teins [26]. The tryptophan residue (W) in position 515 at
the intracellular juxtamembrane boundary normally inhibits
dimerization of the Mpl transmembrane helix and thereby
prevents receptor self-activation [27]. Replacing W515
with another amino acid, for example, leucine, lysine, or
arginine, leads to loss of this inhibition and results in a
constitutively active Mpl. The expression levels of Jak2
and Mpl proteins increase during maturation and constitute
another level of control that is involved in the fine-tuning of
megakaryopoiesis [28]. Activating mutations in the granu-
locyte colony-stimulating factor (G-CSF) receptor,
CSF3R, that also signals through Jak2 were first found in
familial neutrophilia [29] and later in sporadic CNL
[30,31]. They cluster in the extracellular domain of
CSF3R. In some cases, activating mutations can coexist
with truncating mutations in the cytoplasmic domain of
CSF3R found in severe congenital neutropenia [32].Figure 1. Frequency and distribution of acquired gene mutations in hematologic
imate frequencies of the mutations in the different disease entities. ALL 5 acute
myeloid leukemia; CNL 5 chronic neutrophilic leukemia; ET 5
MPN 5 myeloproliferative neoplasms; PMF 5 primary myelofibrosis; PV 5
and thrombocytosis; sAML 5 secondary acute myeloid leukemia.Although CNL is a rare disease and was sometimes difficult
to distinguish from cases of atypical chronic myeloid leuke-
mia (CML), the presence of recurrent CSF3R mutations
will now make it simple to define CNL as an entity related
to PV, ET, and PMF, but with a specific phenotype and
mutational profile. Thus, the theme emerging from these
studies is that Ph-negative MPN is frequently caused by
mutations in JAK2 or in cytokine receptors that depend
on JAK2 for their signaling.
A major gap in the mutational profile of ETand PMF was
recently filled with the discovery of somatic mutations in
calreticulin (CALR) that occur in 20% to 35% of patients
with ET or PMF [33,34]. The CALR and JAK2 mutations
are mutually exclusive in patients with MPN, although
rare exceptions can occur [35]. These CALRmutations result
in a frameshift into an alternative reading frame that alters
the C-terminal sequence of the protein [33,34]. The mutant
CALR protein lacks the C-terminal endoplasmic reticulum
retention signal (KDEL) and most likely has impaired
Ca2þ binding function. Although the mechanisms of how
CALR mutations cause MPN has not yet been resolved
[36], they also ultimately lead to hyperactivity of the
JAK2/Stat signaling pathway in megakaryocytic and granu-
locytic progenitor and precursor cells [33,37]. Interestingly,
patients with CALR mutations and unmutated JAK2 also
respond to JAK2 inhibitors [38,39]. Finally, MPN patients
who do not carry mutations in any of the aforementioned
genes (so-called ‘‘triple-negative’’ MPN cases) also appear
to have hyperactive JAK2 signaling [37]. Therefore, it seems
appropriate to consider the Ph-negative MPN as diseases
driven by hyperactive Jak2/Stat signaling.Other gene mutations frequently occurring in MPN
In addition to the ‘‘phenotypic driver mutations’’ that are
directly linked to hyperproliferation of hematopoietic
cells (Fig. 1), there is a growing list of somatic mutationsmalignancies. The red portions of the horizontal bars indicate the approx-
lymphocytic leukemia; AML 5 acute myeloid leukemia; CML 5 chronic
essential thrombocythemia; MDS 5 myelodysplastic syndromes;
polycythemia vera; RARS-T 5 refractory anemia with ring sideroblasts
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Figure 2. (A) Domain structure of the Jak2 protein. Numbers indicate
amino acid positions within the Jak2 protein. Arrows indicate the positions
of the most frequently mutated regions. The auto-inhibitory effect of the
JH2 domain is indicated in yellow. FERM 5 N-terminal Band 4.1, ezrin,
radixin, moesin domain; JH1 and JH2 5 Jak homology 1 and 2 domains;
SH2 5 Src homology 2 domain. (B) Model of the interactions between the
domains of the Jak2 protein bound to the erythropoietin receptor (EpoR).
F 5 FERM domain; K 5 kinase domain (JH1); SH 5 SH2 domain.
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eration, but can modify and enhance the effects of the
phenotypic driver mutations [40]. These genes belong to
several different categories and function as epigenetic reg-
ulators, transcription factors, or signaling molecules. The
common feature of these gene mutations is that they alone
do not cause a MPN phenotype. They are typically also
frequently found in other hematologic malignancies,
such as myelodysplastic syndrome (MDS) and acute
leukemias. We therefore propose to call them ‘‘nonpheno-
typic driver mutations’’ or perhaps ‘‘important passenger
mutations’’ (Fig. 1). Many of these mutations are sequen-
tially acquired in cells that already carry a mutation in one
of the phenotypic driver genes, most frequently JAK2-
V617F, and are thought to be involved in disease
progression.
Surprisingly, in some patients somatic mutations can
precede the acquisition of the phenotypic driver mutations
and constitute a potentially predisposing mutational event
[41]. Interestingly, the same genes in some patients can
be mutated before JAK2-V617F, and in other patients, after
JAK2-V617F [42]. Thus, the order of events is not uniquely
linked to the gene function. In the case of TET2 mutations,
the order of events, that is, whether the TET2 mutation was
acquired before or after JAK2-V617F, resulted in differ-
ences in phenotype and also in the rate of complications
such as thrombotic events [43]. Two recent studies exam-
ined the broad mutational landscape of patients with PV,
ET, and PMF using exome sequencing or capture-based
next-generation sequencing of a set of 104 genes [34,35].
Both studies found that after JAK2-V617F and CALR,
the most frequent somatic mutations in MPN occur in genes
involved in epigenetic regulation (TET2, DNMT3A, ASXL1,
and EZH2). Mutations in other genes were found at lower
frequencies, many of them in single individual patients,
which will make it difficult to assess their functional and
prognostic relevance. Poor survival and increased risk of
leukemic transformation correlated with the increasing
number of somatic mutations in individual patients
[35,44]. Among the rather rare mutation events, the TP53
mutations stand out, because, when present, they are asso-
ciated with poor prognosis and high risk of progression to
acute myeloid leukemia (AML) [35,45]. Overall, only
about 10% of MPN patients are in the category of ‘‘triple
negative,’’ in which the driver mutation is still unknown.
Triple-negative PMF patients appear to have a less favor-
able prognosis than patients with mutations in JAK2,
CALR, orMPL [46], whereas patients with CALR mutations
tend to have a better prognosis than patients with JAK2 or
MPL mutations [33,47,48]. These studies suggest that the
molecular mutational profiles of MPN patients will likely
become increasingly important in the classification of
MPN subtypes, in determining prognosis, and also in mak-
ing therapeutic decisions.How do mutations in JAK2 increase tyrosine kinase
activity?
JAK2 belongs to the Janus kinase family of proteins, which
comprises four members (JAK1, JAK2, JAK3, and TYK2).
The Jak proteins signal by associating with the intracellular
domains of members of the cytokine receptor superfamily
[49,50]. All JAK family members share a common domain
structure design, with an N-terminal Band 4.1, ezrin, radi-
xin, moesin (FERM) domain that connects the Jak with
the cytokine receptor, a Src homology 2 (SH2) domain,
the Jak-homology 2 (JH2) domain that until recently was
thought to be enzymatically inactive and was therefore
also referred to as the ‘‘pseudokinase’’ domain, and, at
the C-terminus, the enzymatically active tyrosine kinase
domain (Fig. 2A). How JAK2 kinase activity is regulated
and the role of the JH2 domain are not entirely resolved,
in part because the crystal structure of the whole JAK2 pro-
tein is not available. Early work suggested that the JH2
domain exerts a negative regulatory effect on the C-termi-
nal kinase domain [51]. Because the majority of activating
mutations are located in the JH2 domain, it has been sus-
pected that they act by diminishing these inhibitory effects.
Thus, these mutations act through an allosteric mechanism.
Progress has been made recently by demonstrating that the
JH2 domain of JAK2 has a weak dual-type kinase activity
[52]. Disrupting the adenosine triphosphate (ATP) binding
site in the JH2 domain of the wild-type JAK2 had only mi-
nor effects on the kinase activity, but the same disruption in
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[53]. These results suggest that ATP binding to the JH2
domain is required for increased activity of JAK2-V617F.
Another amino acid position in the JH2 domain, F595,
was identified by mutational analysis to be essential for
JAK2-V617F kinase activity, but dispensable for the kinase
activity of the wild-type JAK2 [54]. F595 is predicted to
come into close proximity to F617 in JAK2-V617F and
might constitute a target for selectively blocking the onco-
genic JAK2.
Additional insights into the mechanism by which JH2
regulates JAK activity come from crystallographic studies
and simulation-based models. Although the crystal struc-
ture of the JH2 domain of JAK2-V617F is highly similar
to that of wild-type JH2, it exhibits slight differences in
the ATP binding cleft [55]. A recent computational
simulation-based model proposed that practically all known
disease-causing mutations in JAK2 localize to the surface
of JH2 that engages in the inhibitory interaction with the
JH1 domain [56], although JAK2-V617F remains a notable
exception to this rule. The crystal structure of JH2-JH1 do-
mains of TYK2 is in good agreement with the simulation-
based model for JAK2 [57]. The model proposed by
Silvennoinen and Hubbard predicts that in the absence of
ligand, the cytokine receptor with the two Jak2 proteins is
kept in an inactive state by the tight contact between the
JH2 and JH1 domains (Fig. 2B). This inactive conformation
is in equilibrium with a partially active state, in which JH1
disengages from JH2 and allows some transphosphoryla-
tion, even in the absence of ligand (Fig. 2B, middle panel)
[58]. This partially active conformation is favored by the
presence of a JAK2 mutation, which destabilizes the
JH1–JH2 interaction. A recent report that compared the ef-
fects of JAK2–V617F in mice deficient for Mpl or Tpo is
consistent with this model and supports the view that the
mutant JAK2 is partially active in the absence of ligand,
but is not a constitutively fully active kinase [59]. The
Tpo knockout alone results in a thrombocytopenia pheno-
type that is identical to the phenotype of Mpl knockout
mice [60,61]. On the Mpl knockout background, JAK2-
V617F was unable to sustain thrombopoiesis, and thrombo-
cytopenia was observed, whereas on the Tpo knockout
background, the complex between Mpl and JAK2-V617F
resulted in normalization of the platelet count over time.
These results indicate that in the presence of JAK2-
V617F, Mpl can signal to some degree even in the absence
of ligand, but these signals are not strong enough to induce
a full MPN phenotype [59]. For full activity, ligand binding
to the extracellular domain of the receptor is necessary,
which induces additional structural rearrangement in the
cytoplasmic domains that bring the kinase domains into
even closer proximity, possibly through rotation of the
transmembrane helices, and allow efficient transphosphory-
lation (Fig. 2B, right panel). The dimer geometry also plays
a role in determining the level of activation of othercytokine receptors, such as the erythropoietin receptor
(EpoR) [62].
JAK2 inhibitors that displace ATP from its binding site
in the JH1 domain of JAK2 have been developed for use
in patients with MPN [63,64]. Ruxolitinib, a JAK1/JAK2
inhibitor, was the first drug to be approved because of its
effects on reducing spleen size and improving quality of
life [65,66]. Other ATP-competitive kinase inhibitors,
including pacritinib and momelotinib, that differ in their
specificities for JAK2 and other tyrosine kinases are under-
going clinical trials [63,64]. The lack of specificity for the
mutated JAK2 explains why the mutant allele burden in
most cases is only slightly reduced or unchanged and also
why MPN patients with unmutated JAK2 are responsive.
These agents are limited by dose-dependent suppression
of normal hematopoiesis because they also inhibit the
wild-type JAK2. Indeed, Jak2 knockout is embryonic lethal
because of the failure of definitive erythropoiesis [67], and
induced conditional deletion of Jak2 in adult mice resulted
in severe anemia and thrombocytopenia leading to death of
the animals [68–70].
An interesting phenomenon of ‘‘persistence’’ that occurs
when JAK2-V617F mutated hematopoietic cells grow under
chronic suppression by ruxolitinib has been described [71].
These cells escape inhibition and maintain signaling by het-
erodimerization between JAK2-V617F and JAK1 or TYK2
at the cytoplasmic domain of the cytokine receptors. This
persistence can be overcome by inhibition with compounds
that bind JAK2 in the inactive state (‘‘type II’’ inhibitors)
[72]. Ruxolitinib and other currently developed JAK2 in-
hibitors target the ATP-binding pocket and stabilize the
active conformation of the JAK kinases (‘‘type I’’ inhibi-
tors). The more profound inhibition of JAK2-V617F activ-
ity by a type II inhibitor (CHZ868) is sufficient to abrogate
the persistence mechanism through heterodimerization with
JAK1/Tyk2. Interestingly, this type II inhibitor reduced the
JAK2-V617F mutant allele burden in mouse models of
MPN [73]. Our increasing understanding of the mecha-
nisms of how the mutant JAK2 activates signaling provides
new perspectives from which to develop JAK inhibitors that
are more potent and at the same time selective for the onco-
genic forms of JAK2. With such new compounds, the goal
in patients with MPN will be to induce molecular remission
and substantially alter the course of the disease.Dependence of oncogenic JAK2 mutants on downstream
signaling components
The signal transducer and activator of transcription (Stat)
proteins are present in the cytoplasm in an inactive form
and constitute primary targets of phosphorylation by acti-
vated JAK kinases. The phosphorylated Stats dimerize
through their SH2 domains and translocate into the nucleus,
where they participate in transcription [50,74]. Several of
the seven Stat family members can be activated by JAK2,
Figure 3. Model summarizing the known and hypothetical roles of Stat
proteins in erythropoiesis and megakaryopoiesis in mice expressing
JAK2-V617F. Arrows indicate stimulatory effects; T-Bars indicate inhibi-
tory effects. Epo 5 erythropoietin; EpoR 5 erythropoietin receptor;
Mpl 5 thrombopoietin receptor; Tpo 5 thrombopoietin.
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Stat5b are encoded by separate genes, but the correspond-
ing proteins are closely related and in part redundant in
their functions. The germline Stat5a/5b double knockout
has a more severe hematopoietic phenotype (i.e., anemia)
that either of the single knockouts [75,76]. Initial studies
suggested that Stat5a and Stat5b are essential for embry-
onic erythropoiesis, but dispensable for adult erythropoi-
esis. Later, through use of a conditional Stat5a/b
knockout, Stat5a/b/ mice were found to be perinatal le-
thal because of severe anemia [77], which was in part
due to decreased expression of the transferrin receptor1
(TfR1) [78,79]. Deletion of Stat5a/b in retroviral and
knock-in JAK2-V617F mouse models abrogated the MPN
phenotype and normalized the blood counts (Fig. 3A)
[80,81]. These studies indicate that Stat5a/b is essential
for the manifestation of JAK2-V617F-driven MPN. Conse-
quently, Stat5a/b could represent a target for inhibition, and
recently, small molecular Stat5 inhibitors have been derived
that can also be used in vivo [82].
Mice deficient in Stat1 exhibit no developmental abnor-
malities, but have compromised innate immunity to viral
disease because of a lack of responsiveness to interferon
stimuli [83]. Further work with these mice revealed delayed
erythroid differentiation in bone marrow and spleen and a
net decrease in total body colony-forming unit–erythroid
(CFU-E), although hemoglobin and red cell parameters in
peripheral blood remained normal [84]. Megakaryocytes
from Stat1-deficient mice also exhibited defective
polyploidization, and Stat1 was found to promote
megakaryopoiesis downstream of GATA1 [85]. Studies of
burst-forming unit–erythroid (BFU-E) colonies from
JAK2-V617F-positive MPN patients revealed that in-
creased activation of Stat1 may constrain erythroid differ-
entiation and favor expression of an ET phenotype [86].
Consistently, Stat1 knockout in the JAK2-V617F-driven
mouse model of MPN decreased megakaryopoiesis and
favored erythropoiesis (Fig. 3B) [87]. Tpo, Epo, and also
g-interferon, through their receptors, use Jak2 to phospory-
late Stat1 [88–90], and the presence of JAK2-V617F is ex-
pected to augment Stat1 activation. g-Interferon signaling
was increased in JAK2-V617F-heterozygous erythroblasts
from patients with ET, but not those with PV [86]. In line
with this finding, serum levels of g-interferon were
increased in ET patients in comparison with PV patients
and could favor the ET phenotype triggered by the JAK2-
V617F mutation [87].
Constitutional Stat3 disruption in mice led to early em-
bryonic lethality, most likely from a defect in functions of
visceral endoderm [91]. Three different strains with a con-
ditional knockout of Stat3 have been generated [92–94].
Deletion of Stat3 in hematopoiesis impaired processes
that are dependent on gp130 signaling [92,95,96], and
Stat3 deletion also induced a Crohn’s disease-like
604 R.C. Skoda et al./ Experimental Hematology 2015;43:599–608pathology and lethality [94]. In mice expressing the mutant
JAK2-V617F, loss of Stat3 had different effects depending
on whether Stat3 is deleted in hematopoietic cells only or
in a wide range of tissues. In a setting in which uninduced
bone marrow cells were transplanted into lethally irradiated
recipients and expression of JAK2-V617F, as well as the
Stat3 knockout, was induced after the mice were fully re-
constituted, homozygous loss of Stat3 had no effect on
the PV phenotype, but the platelet counts were increased
and led to a trend toward more severe myelofibrosis than
in mice expressing the wild-type Stat3 (Fig. 3C) [97]. A
similar trend toward increased platelet counts was also
observed in nontransplanted mice with the same genotypes,
but these mice exhibited early lethality already 2–4 weeks
after induction and therefore had less time to show differ-
ences in phenotype [98]. Loss of Stat3 in JAK2-V617F
mice led to a compensatory increase in Stat1 expression
and phosphorylation that likely contributes to the increase
in platelets (Fig. 3C) [97,98]. The two reports differ with
respect to granulopoiesis. Whereas one report found that
neutrophils were increased in JAK2-V617F knock-in mice
with deleted Stat3 in transplanted and nontransplanted
mice [98], the other report using JAK2-V617F transgenic
mice with the same conditional Stat3 strain found decreased
neutrophil counts in the transplanted mice [97], but a trend
toward an increase in nontransplanted mice (Grisouard J
and Skoda RS, unpublished results). The reasons for these
differences are currently unclear, in addition to the use of
two different models of JAK2-V617F, the induction of
JAK2-V617F and Stat3 deletion in the transplanted mice
was performed after reconstitution in one study [97],
whereas the other study had already performed the induction
in the bone marrow cells of the donor [98]. In another MPN
mouse model expressing the MPL-W515L mutation, pan-
hematopoietic Stat3 deletion attenuated cytokine secretion
and resulted in lower white blood cell counts, lower spleen
weights, and a reduced degree of reticulin fibrosis, whereas
Stat3 deletion restricted to MPL-W515L-expressing he-
matopoietic cells did not reduce disease severity or cytokine
production [99]. Together, these studies indicate that Stat3 is
important for cytokine production by malignant and nonma-
lignant cell populations, which both participate in the regu-
lation of myeloid cell expansion in MPN [100]. However,
the lethality induced by deletion of Stat3 in JAK2-V617F-
expressing mice and the lack of beneficial effects on the
MPN phenotype make Stat3 a less likely drug target for
the treatment of MPN.
Although the Stat proteins are important elements in the
signaling by oncogenic JAK2, with Stat5 being the key
player, other signaling pathways downstream of JAK2 are
also involved, including the PI3K/Akt/mTOR and Ras/
MAPK signaling pathways. Although MAPK inhibitors
have not been examined in the context of MPN, inhibitors
of the PI3K/Akt/mTOR pathway were studied in vitro and
in mouse models, and some are already in clinical trials inpatients with MPN. The inhibition of PI3K/AKT signaling
affected the growth of both JAK2-V617F- and MPL-
W515L-expressing cells and synergized with ruxolitinib
in suppressing the growth of JAK2-V617F mutant SET2
cells [101]. The combination of JAK2/JAK1 and PI3K in-
hibitor reduced spleen weight in nude mice inoculated
with Ba/F3 cells expressing JAK2-V617F. It also exerted
strong inhibitory effects on erythropoietin-independent
erythroid colonies from MPN patients and JAK2-V617F
knock-in mice [102]. A dual PI3K/mTOR inhibitor in com-
bination with ruxolitinib produced significant synergism in
different preclinical models of MPN expressing JAK2-
V617F mutation [103,104]. The mTOR inhibitors alone
and in combination with JAK2 inhibitors effectively inhibit
cells of myeloproliferative neoplasms [105]. The early clin-
ical studies indicated some beneficial effects that need to be
followed up [103].
In rare cases, mutations in genes that encode modifiers
of JAK2 signaling have also been detected in MPN. LNK
negatively regulates JAK2 activation through its SH2
domain and inhibits Epo-R and Mpl signaling [106,107].
Mutations that interfere with LNK function have been
described in ET and PMF patients and in patients progress-
ing to leukemia [108,109]. Similarly, mutations in the
multifunctional adapter protein CBL that targets proteins
for ubiquitination have been found in some cases of MPN
[110].Gene mutations involved in MPN disease initiation or
progression
Familial clustering of MPN with acquired somatic muta-
tions in driver genes such as JAK2-V617F, MPL-W515,
and CALR in pedigrees with autosomal dominant transmis-
sion of MPN indicated that germline mutations in as yet
unknown genes can exert a strong predisposing effect on
MPN occurrence [111–113]. Germline polymorphisms in
the JAK2 locus referred to as the 46/1 or GGCC haplotype
were found in population-based studies to be associated
with JAK2-V617F [114–116] and, to a lesser degree, with
MPL-W515 [117]. Recently, additional gene loci including
MECOM, TERT, and HBS1L-MYB have also been found to
be associated with predisposition to MPN [118,119]. How-
ever, the increase in odds ratios by these frequent polymor-
phisms is too low to account for the clustering of MPN in
large pedigrees.
Although the genes involved in familial MPN still need
to be identified, there are also well-documented cases of
somatic gene mutations that occurred before the acquisition
of the actual driver gene mutation [41,42,120–122]. The
‘‘fertile ground’’ hypothesis is currently the preferred model
to explain how these mutations collaborate with the driver
gene mutation in initiating MPN [114]. There is currently
no evidence for the alternative model, which proposed
that hypermutability, as a consequence of the predisposing
605R.C. Skoda et al./ Experimental Hematology 2015;43:599–608mutations, would favor the acquisition of JAK2-V617F and
other driver gene mutations. One of the predictions of the
fertile ground model is that JAK2-V617F alone may not
be very efficient at initiating MPN. Indeed, studies reported
that the frequency of somatic JAK2-V617F mutations in the
general population exceeds the frequency of MPN [123],
suggesting that additional events may be required for
MPN manifestation. In mouse models, JAK2-V617F alone
was capable of initiating MPN from single transplanted
stem cells, but with a low efficiency, leaving open the pos-
sibility that additional mutational events could synergize in
disease initiation [124]. Because some mutations in epige-
netic regulators, for example, Tet2, have been found to
expand the hematopoietic stem cell and progenitor pool
[125,126], it seems likely that they could favor the early
clonal expansion of a JAK2-V617F mutated stem cell.
The role of mutations in genes encoding epigenetic reg-
ulators is clearly not limited to disease initiation of MPN
(Fig. 1). Although mutations in epigenetic regulators,
when mutated alone, in most cases result in either no or
only minor phenotypes, their presence in combination
with other mutational events can also affect disease evolu-
tion. Recently, JAK2-V617F, in combination with loss of
Tet2, was found to have synergistic effects and resulted in
MPN disease progression [127,128]. Typically, the muta-
tions in epigenetic regulators are also frequently found in
other hematologic malignancies, such as MDS and AML;
and some of the gene mutations, such as TET2 and
ASXL1, are more frequent in MDS than in MPN (Fig. 1).
A clinically important aspect of MPN disease progression
is the transformation to AML. Some studies suggest that
the presence of mutations in TET2, EZH2, and ASXL1
increases the risk of secondary AML [35,129,130]. The
presence of mutations in TP53 in patients with MPN is
particularly tightly correlated with progression to secondary
AML [35,45]. In mouse models, loss of Tp53 accelerated
JAK2-V617F-driven MPN and resulted in a phenotype
resembling acute leukemia [131].Outlook
Major progress has been achieved in understanding the
molecular pathogenesis of MPN in a very short period of
10 years. We now have a near-complete picture of the muta-
tional landscape of MPN with only a few gaps left. The
current technologies allow mutational screening of MPN
patients at diagnosis, and this knowledge will increasingly
translate into predictions of complications and survival and
will influence therapeutic decisions. Already today we
have a large number of new compounds in clinical trials in
patients with MPN. Some of them were discussed here; other
promising approaches to MPN therapy were beyond the
scope of this review and include inhibitors of the chaperone
HSP90 [132], the telomerase inhibitor imetelstat [64], b3-
adrenergic agonist [133], and HDAC inhibitors [64]. As weare already in the postgenomic era, the availability of mouse
models carrying mutations that are found in MPN patients
will be increasingly important to clarify the functional rele-
vance and the interplay between the different mutations.References
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